• President Biden signs the Inflation Reduction Act surrounded by members of congress and backed by American flags in the White House.
    Image attribution tooltip
    Drew Angerer via Getty Images

    3 ways pharma can prep for Biden’s sweeping drug pricing policies

    Now that Medicare will be able to negotiate drug prices under the Inflation Reduction Act, the industry can expect to see some changes. Here are some tips on how to navigate the changing tide.

    By Aug. 18, 2022
  • Teresa Bitetti Takeda Oncology
    Image attribution tooltip
    Diego Camargo/PharmaVoice

    Woman of the Week: Takeda Oncology’s Teresa Bitetti

    Upon joining Takeda Pharmaceuticals as president of the global oncology unit, Teresa Bitetti had two important goals: to transform the business and create greater synergies between commercial and R&D operations.

    By Aug. 17, 2022
  • George Magrath wears blue scrubs and sits over a patient.
    Image attribution tooltip

    Permission granted by George Magrath. 

    The CEO in the ophthalmologist’s coat

    In balancing two roles — Lexitas CEO and practicing physician — George Magrath brings a patient-first perspective to developing and advancing eye treatments.

    By Alexandra Pecci • Aug. 16, 2022
  • Nasal spray
    Image attribution tooltip
    Evgenyi_Eg via Getty Images

    Right under our noses: Could COVID-19 vaccines be better as nasal spray?

    Nasal vaccines under development by Codagenix, Xanadu Bio and others have the potential to finally help reduce virus transmission and breakthrough infections.

    By Kelly Bilodeau • Aug. 16, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    The FDA is mulling an OTC approval for a birth control. Will politics factor in?

    Analysts are watching how cultural and political debates around reproductive rights may impact HRA Pharma's OTC birth control application.

    By Aug. 15, 2022
  • Cupped hands reaching out with medical icons in background.
    Image attribution tooltip

    Adobe Stock / Art N More

    Sponsored by EVERSANA

    Reimagining the patient care ecosystem

    Patient demand for telehealth and a flood of industry challenges are disrupting the traditional healthcare landscape. But what if delivery of care made it more accessible and provided greater transparency throughout the process?

    Aug. 15, 2022
  • ARLINGTON, VA - JUNE 05: Recently laid off worker Lyn Talent receives a free Botox injection during an event called the "The Botox Bailout."
    Image attribution tooltip
    Win McNamee/Staff via Getty Images

    Despite AbbVie’s Botox prowess, underdog Galderma has leveraged soft skills to succeed in aesthetics

    Galderma may not have the biggest name in aesthetics, but as the sector grows past pandemic lows, the company is relying on its people to build a loyal customer base.

    By Aug. 11, 2022
  • Image attribution tooltip
    E+ via Getty Images

    As pharma M&A ramps up, U.S. execs are bullish on more deals

    What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.

    By Aug. 11, 2022
  • cell therapy infusion
    Image attribution tooltip
    Stock via Getty Images

    4 ways to nail the launch of your cell therapy

    A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.

    By Aug. 10, 2022
  • Seen from behind, a clinician is using a cell phone and checking a patient's electronic health record on a laptop.
    Image attribution tooltip
    iStock via Getty Images

    How real world evidence is impacting rare disease drug development

    By Kim Ribbink • Aug. 9, 2022
  • A baby harp seal pup lays on ice in the White Sea.
    Image attribution tooltip
    iStock via Getty Images

    Turning harp seal contraceptives into a ‘new genre’ of cancer treatments

    With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.

    By Alexandra Pecci • Aug. 9, 2022
  • CEO pay
    Image attribution tooltip
    Stock via Getty Images

    Are Big Pharma CEOs earning their pay?

    While compensation packages at the top may not always reflect value, it’s not necessarily an industrywide problem.

    By Kelly Bilodeau • Aug. 8, 2022
  • monkeypox vax
    Image attribution tooltip
    Mario Tama via Getty Images

    The ‘alarming’ spread of Monkeypox — by the numbers

    With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’

    By Aug. 8, 2022
  • Pills, blister packs, medical bottles, laptop
    Image attribution tooltip
    MJ_Prototype via Getty Images

    Generic subscription services like Mark Cuban’s promise cheaper drugs — but will it work?

    Companies like Cost Plus Drugs and DiRx can bring generics directly to consumers at a fraction of the price, but whether it’s enough to fix the inflated U.S. healthcare system is yet to be seen.

    By Aug. 4, 2022
  • A hand picks a blue figurine out of rows of similar wooden figurines.
    Image attribution tooltip
    Ivan Balvan via Getty Images

    Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires

    How these latest executive personnel changes are impacting the industry. 

    By Aug. 3, 2022
  • A collage of pnk, blue and orange bacteria-like blobs float around against a dark blue background.
    Image attribution tooltip
    iStock via Getty Images

    Taking probiotics where they’ve never gone before

    How Seed Health is transforming the microbiome therapeutic market with its pharma-focused drug development approach.

    By Aug. 2, 2022
  • A physician in a white scrubs assists a blue-shirted patient.
    Image attribution tooltip
    iStock via Getty Images

    ‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients

    EverythingALS aims to speed drug development through improved diagnostics.

    By Kelly Bilodeau • Aug. 2, 2022
  • Artifical intelligence
    Image attribution tooltip
    Olemedia via Getty Images

    How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond

    WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.

    By Kim Ribbink • Aug. 1, 2022
  • Catherine Owen
    Image attribution tooltip

    Permission granted by Catherine Owen.


    A glimpse inside Bristol Myers Squibb’s integration with Celgene

    Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.

    By Aug. 1, 2022
  • A nurse in green scrubs puts a smart watch on a patient in a grey, blue and orange striped shirt.
    Image attribution tooltip
    Giuseppe Lombardo via Getty Images

    Personalized data could bring PhysIQ to the forefront of clinical trial evolution

    The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.

    By July 28, 2022
  • A person points a pen at a computer with a green line graph. A blurred computer in the background shows other graphs.
    Image attribution tooltip
    iStock via Getty Images

    What’s next for Biogen? Here’s what executives are saying

    A trickling launch for Aduhelm and a middling earnings report give Biogen executives a lot to talk about. Is there hope?

    By July 27, 2022
  • A view of the Capitol Dome from below with an American flag waving in the wind on the left side and blue skies in the background.
    Image attribution tooltip
    iStock via Getty Images

    Democrats think they've found a balance between drug innovation and pricing negotiation

    A look at Congress’ push to pass drug pricing reform and why the latest attempt could actually succeed.

    By July 26, 2022
  • Neuron
    Image attribution tooltip
    koto_feja via Getty Images

    A 'total waste'? Drug developers worry if two decades of Alzheimer's research were pointed at the wrong targets

    The latest trial failures in Alzheimer's have shown cracks in the foundation of ingrained theories like amyloid plaque clearance. What will it take to move forward?

    By July 25, 2022
  • A man walks out of the Pfizer world headquarters building.
    Image attribution tooltip
    Chris Hondros / Staff via Getty Images

    Behind Pfizer's new quest to target a 'transformation' in pharma

    A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.

    By Kelly Bilodeau • July 25, 2022
  • J&J CEO Joaquin Duato
    Image attribution tooltip
    Mike Coppola/Staff via Getty Images

    With big changes ahead for J&J and Novartis, here's what the companies' execs are talking about

    Both J&J and Novartis are making — or considering — big shifts in their fundamental company makeup.

    By July 21, 2022